Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2018, Article ID 2349021, 4 pages
https://doi.org/10.1155/2018/2349021
Case Report

EGFR T790M-Positive Lung Adenocarcinoma Metastases to the Pituitary Gland Causing Adrenal Insufficiency: A Case Report

1Department of Internal Medicine, Sinai Hospital, Baltimore, MD, USA
2University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA
3Department of Endocrinology, Sinai Hospital, Baltimore, MD, USA

Correspondence should be addressed to Michael L. Adashek; ude.mosvw.oetso@kehsadam

Received 25 March 2018; Accepted 17 May 2018; Published 31 May 2018

Academic Editor: Giovanni Tallini

Copyright © 2018 Michael L. Adashek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Rahmathulla, S. A. Toms, and R. J. Weil, “The molecular biology of brain metastasis,” Journal of Oncology, vol. 2012, Article ID 723541, 16 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Li, J. Lian, S. Han et al., “Applicability of graded prognostic assessment of lung cancer using molecular markers to lung adenocarcinoma patients with brain metastases,” Oncotarget, vol. 8, no. 41, pp. 70727–70735, 2017. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Imaoka, F. Kuranishi, Y. Ogawa, H. Okuda, and M. Nakahara, “Adrenal failure due to bilateral adrenal metastasis of rectal cancer: a case report,” International Journal of Surgery Case Reports, vol. 31, pp. 1–4, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. M. R. Huecker and E. Dominique, “Adrenal, insufficiency,” in StatPearls, StatPearls Publishing LLC, Treasure Island, FL, USA, 2017, NBK441832 [bookaccession]. View at Google Scholar
  5. M. Quinkler, B. Ekman, C. Marelli et al., “Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency,” Endocrine Connections, vol. 6, no. 1, pp. 1–8, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Lutz, M. Stojkovic, M. Schmidt, W. Arlt, B. Allolio, and M. Reincke, “Adrenocortical function in patients with macrometastases of the adrenal gland,” European Journal of Endocrinology, vol. 143, no. 1, pp. 91–97, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. C. D’Antonio, A. Passaro, B. Gori et al., “Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies,” Therapeutic Advances in Medical Oncology, vol. 6, no. 3, pp. 101–114, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Komninos, V. Vlassopoulou, D. Protopapa et al., “Tumors metastatic to the pituitary gland: case report and literature review,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 2, pp. 574–580, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Melmed, F. F. Casanueva, A. R. Hoffman et al., “Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 2, pp. 273–288, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. S. G. Wu and J. Y. Shih, “Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer,” Molecular Cancer, vol. 17, no. 1, p. 38, 2018. View at Publisher · View at Google Scholar · View at Scopus
  11. NeoGenomics, “EGFR T790M germline mutation analysis,” 2018, May 2018, https://neogenomics.com/test-menu/egfr-t790m-germline-mutation-analysis. View at Google Scholar
  12. C. Demuth, A. T. Madsen, B. Weber, L. Wu, P. Meldgaard, and B. S. Sorensen, “The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment,” BMC Cancer, vol. 18, no. 1, p. 191, 2018. View at Publisher · View at Google Scholar · View at Scopus
  13. “FDA approves first blood test to detect gene mutations associated with non-small cell lung cancer,” June 2016, https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504488.htm.
  14. B. Weber, P. Meldgaard, H. Hager et al., “Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays,” BMC Cancer, vol. 14, no. 1, pp. 294–2407, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Ballard, J. W. T. Yates, Z. Yang et al., “Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity,” Clinical Cancer Research, vol. 22, no. 20, pp. 5130–5140, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Alegre, J. P. Fusco, P. Restituto et al., “Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value,” Tumor Biology, vol. 37, no. 10, pp. 13687–13694, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Okauchi, H. Osawa, K. Miyazaki, M. Kawaguchi, and H. Satoh, “Paradoxical response to osimertinib therapy in a patient with T790M-mutated lung adenocarcinoma,” Molecular and Clinical Oncology, vol. 8, no. 1, pp. 175–177, 2017. View at Publisher · View at Google Scholar